Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nippon Chemiphar to Launch Amaryl AGs on June 20
June 13, 2025
- Takeda’s Livmarli, HyQvia Now Available in Japan
June 13, 2025
- Boehringer Files Nerandomilast for Pulmonary Fibrosis in Japan
June 13, 2025
- Pfizer Pushes Back Champix Re-Supply Plan on Regulatory Delay
June 12, 2025
- AbbVie Japan Looks to Double Sales by 2029 with Rinvoq and Skyrizi as Engines
June 12, 2025
- Prashant Nikam to Take Over Helm of MSD Japan
June 12, 2025
- Takeda Seeks Japan Nod for Vonvendi Use in Patients Under 18
June 11, 2025
- Enhertu Enters PIII for 1st-Line Endometrial Cancer Use: Daiichi
June 11, 2025
- Taking on Solid Tumors - 5: Genmab Pursuing Unique T-Cell Engager Program for Lung Cancer
June 11, 2025
- Taking on Solid Tumors - 4: With 2 Late-Stage Assets in Wings, Will AstraZeneca Reshape CP Inhibitor Landscape?
June 10, 2025
- SSP Files for OTC Switch of Tadalafil in Japan
June 10, 2025
- Nipro, Samsung Bioepis Tie Up on Biosimilar Business in Japan
June 10, 2025
- Sawai Follows Fuso to Challenge Remitch Patent Ruling
June 10, 2025
- Otsuka’s Sibeprenlimab Scores Positive Results in PIII: Interim Analysis
June 9, 2025
- Sumitomo Divests Canadian Business to Knight
June 9, 2025
- BMS Files Label Expansion of Sotyktu for Psoriatic Arthritis in Japan
June 9, 2025
- Tivdak Offers Valuable New Option as 2nd-Line Cervical Cancer Therapy: Oncologist
June 9, 2025
- Antibody Market to Reach 2.6 Trillion Yen in 2034: Fuji Keizai
June 9, 2025
- Moderna Files Updated Spikevax for LP.8.1 Strain in Japan
June 9, 2025
- Fuso Takes Remitch Patent Case to Top Court
June 9, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…